76.50 -0.18 (-0.23%)
Pre-Market: 9:01AM EDT
|Bid||0.00 x 800|
|Ask||0.00 x 800|
|Day's Range||75.90 - 79.04|
|52 Week Range||64.72 - 126.98|
|Beta (3Y Monthly)||1.83|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Neurocrine Biosciences Inc NASDAQ/NGS:NBIXView full report here! Summary * Bearish sentiment is low * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is low for NBIX with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NeutralETF activity is neutral. The net inflows of $4.77 billion over the last one-month into ETFs that hold NBIX are among the highest of the last year, but the rate of growth is slowing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Is Neurocrine Biosciences an Attractive Pick after Q1 Results?(Continued from Prior Part)Opicapone in Parkinson’s DiseaseIn its first-quarter earnings conference call, Neurocrine Biosciences (NBIX) highlighted plans to submit an NDA (new drug
Is Neurocrine Biosciences an Attractive Pick after Q1 Results?Stock price movementsNeurocrine Biosciences (NBIX) reported first-quarter results on April 29. The company reported total revenues of $138.40 million, a YoY rise of 94.70%. Posted
Here's a roundup of top developments in the biotech space over the last 24 hours. Stock In Focus G1 Therapeutics Plans Regulatory Submission For Bone Marrow Preservation Drug G1 Therapeutics Inc (NASDAQ: ...
The San Diego-based company said it had a loss of $1.12 per share. The results missed Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment Research was for a loss ...
Is Biogen continuing to strike out? Coming off the company's first earnings call since its lead Alzheimer's disease drug failed, some analysts think so.
Like everyone else, elite investors make mistakes. Some of their top consensus picks, such as Amazon, Facebook and Alibaba, have not done well in Q4 due to various reasons. Nevertheless, the data show elite investors' consensus picks have done well on average over the long-term. The top 15 S&P 500 stocks among hedge funds at […]
Small-cap and large-cap companies receive a lot of attention from investors, but mid-cap stocks like Neurocrine Biosciences, Inc. (NASDAQ:NBIX), with a market cap of US$7.7b, are often out of the spotlight. While they are less talk...
Analysts Are Feeling Good about These Biotech Stocks in March(Continued from Prior Part)Analysts’ recommendations and target priceWall Street analysts expect a potential upside of 26.66% for Neurocrine Biosciences (NBIX) based on the company’s
Sage Therapeutics (NYSE:SAGE) is popped yesterday on FDA approval of its postpartum depression drug -- the first of its kind. So far, SAGE stock is up 3%, but this on the back of a more than 70% run up year-to-date in anticipation of the news.Source: Shutterstock Postpartum depression is a sometimes life-threatening condition that can happen before or after a woman gives birth to a child. In serious cases, she may harm herself or her child as a result. It is estimated that as many as one in nine women who have recently given birth suffer from postpartum depression, but it is a little talked about condition, so up to half of cases go unreported. But now there is a specific treatment. Zulresso was approved as an IV treatment to be administered in a certified healthcare facility over 2.5 days. With no other drug on the market to treat postpartum depression, Sage has no competition to worry about. And with a market cap of $7.8 billion -- lower than the addressable market potential for this treatment -- biotech investors cannot afford to ignore SAGE stock. Efficacy of ZulressoIn two clinical studies where participants received Zulresso or placebo, those who were treated showed an improvement of depressive symptoms compared to the placebo group.InvestorPlace - Stock Market News, Stock Advice & Trading TipsSage Therapeutics recently raised $500 million through a SAGE stock offering on February 25. This cash infusion will give the company the capital it needs to roll out Zulresso following its approval. Sage Is Sitting on Plenty of CashIn its fourth quarter, SAGE lost $3.38 per share on revenue of just $0.28 million. But it ended the period with $922.8 million in cash, cash equivalents and marketable securities. This is up from $518.8 million at the end of 2017. Sage's management said it has enough cash on hand to fund expenses until the second half of next year (2020).Sage accelerated its R&D activity, which increased such expenses to $88.8 million, up from $50.9 million. IT spent $282.1 million in R&D for the full year 2018. Sage spent more on discovery efforts associated with identifying new clinical candidates, along with additional indications in its three CNS franchises. After the FDA approved Zulresso, R&D costs associated with Phase 3 clinical development may shift to marketing and G&A spend instead. Ahead of the launch, Sage spent $201.4 million in G&A costs, up sharply from $62.9 million last year. Sage's Full PipelineWithin Sage Therapetics' pipeline are more promising drugs. For example, SAGE-217 is being tested for efficacy in treating major depressive disorder, postpartum depression, biopolar depression and insomnia. Meanwhile, SAGE-324 has an indication for Parkinson's Disease, Essential Tremor and Epileptiform Disorders. The Bottom Line on Sage StockEven after Sage stock's recent rally, 10 analysts who follow the stock have an average12-month target price of $198 -- according to Tipranks. That's more than 25% upside. Biotech investors who are looking for similar stocks could consider Neurocrine Bio (NASDAQ:NBIX) or Zogenix (NASDAQ:ZGNX). * 5 Cloud Stocks to Help Your Portfolio Fly Sage Therapeutics has a promising drug that will not face any competition. Markets already expect strong sales for Zulresso. The company has a strong cash balance and plenty of more drugs in the pipeline. For these reasons, biotech investors should take a serious look at SAGE stock.Disclosure: As of this writing, the author did not hold a position in any of the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Invincible Stocks Leading The Bull Market Higher * 5 Dow Jones Stocks Coming to Life * 7 of the Best High-Yield Funds for 2019 and Beyond Compare Brokers The post Sage Stock Pops on FDA Approval for Postpartum Depression Drug appeared first on InvestorPlace.
Acadia Pharmaceuticals and Neurocrine Biosciences stand out as potential takeover candidates among biotech stocks, an analyst said Friday. Both are working on central nervous system drugs.
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) is a company with exceptional fundamental characteristics. Upon building up an investment case for a stock, we should look at various aspects. In the case ofRead More...
Voyager (Nasdaq: VYGR) is expanding its partnership with pharmaceutical company AbbVie (Nasdaq: ABBV), launching a research effort to develop antibody treatments that can be delivered directly to the brain and target a protein called alpha-synuclein.
Neurocrine Biosciences Inc engages in the discovery and development of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. Warning! GuruFocus has detected 2 Warning Signs with NBIX. For the last quarter Neurocrine Biosciences Inc reported a revenue of $131.5 million, compared with the revenue of $94.52 million during the same period a year ago.